| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/26/2001 | EP1136562A2 Feline leukemia virus vaccines |
| 09/26/2001 | EP1136557A1 Proteins and polypeptides from Haemophilus influenzae involved in paracytosis, nucleotide sequences encoding them and uses thereof |
| 09/26/2001 | EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/26/2001 | EP1136500A2 Seroreactive regions from the HPV proteins E1 and E2 |
| 09/26/2001 | EP1136077A1 Preparations containing virus-like particles as immunopotentiators administered through the mucosa |
| 09/26/2001 | EP1135688A2 Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| 09/26/2001 | EP1135516A1 Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells |
| 09/26/2001 | EP1135509A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/26/2001 | EP1135504A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 09/26/2001 | EP1135501A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/26/2001 | EP1135498A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 09/26/2001 | EP1135497A1 Polypeptides capable of interacting with the human topoisomerase iii alpha |
| 09/26/2001 | EP1135495A2 Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| 09/26/2001 | EP1135485A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 09/26/2001 | EP1135484A2 Gtpase associated proteins |
| 09/26/2001 | EP1135482A1 Cancer cell vaccine |
| 09/26/2001 | EP1135477A1 Humanized monoclonal antibodies |
| 09/26/2001 | EP1135476A1 Biological compositions, components thereof and uses therefor |
| 09/26/2001 | EP1135468A1 Virus vectors and methods of making and administering the same |
| 09/26/2001 | EP1135415A1 Humanized antibodies to gamma-interferon |
| 09/26/2001 | EP1135414A2 Allo and auto-reactive t-cell epitopes |
| 09/26/2001 | EP1135412A2 Tumor necrosis factor receptor homologue-1 (trh1) |
| 09/26/2001 | EP1135409A1 Decorin binding proteins dbp a and b and genes encoding them |
| 09/26/2001 | EP1135408A1 Hbv core antigen particles with multiple immunogenic components attached via peptide ligands |
| 09/26/2001 | EP1135167A2 Methods and formulations for reducing circulating antibodies |
| 09/26/2001 | EP1135166A1 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 09/26/2001 | EP1135162A2 Ordered molecular presentation of antigens, method of preparation and use |
| 09/26/2001 | EP1135160A2 Boron neutron capture therapy using pre-targeting methods |
| 09/26/2001 | EP1135159A2 Peptide-based vaccine for influenza |
| 09/26/2001 | EP1135158A2 Enhanced vaccines |
| 09/26/2001 | EP1135153A1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 09/26/2001 | EP1135143A1 Immunomodulatory methods using carbohydrate antigens |
| 09/26/2001 | EP1135107A1 Utilisation of capsules containing one or more antigenic substances for the prevention and/or treatment of autoimmune diseases |
| 09/26/2001 | EP1135025A1 Plasmid maintenance system for antigen delivery |
| 09/26/2001 | EP0809653B1 Helicobacter pylori antigen |
| 09/26/2001 | EP0804581B1 Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
| 09/26/2001 | EP0771325B1 Process for modifying the stability of antibodies |
| 09/26/2001 | EP0767796B1 Chemotactic protein |
| 09/26/2001 | EP0495910B1 Production and use of human nm23-h2 protein and antibodies therefor |
| 09/26/2001 | CN1314942A Newcastle disease virus infection clones, vaccine and diagnostic assays |
| 09/26/2001 | CN1314940A Temperature-sensitive and cold-adapted human parainfluenza virus type 2(HPIV-2) and vaccines based on such virus |
| 09/26/2001 | CN1314917A Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinase |
| 09/26/2001 | CN1314916A Cancer antigens based on tumor suppressor gene WT1 product |
| 09/26/2001 | CN1314809A Method of vaccination of newly hatched poultry |
| 09/26/2001 | CN1314412A New polypeptide-human glucose transport similar protein 18 and polynucleotide for coding such polypeptide |
| 09/26/2001 | CN1314184A Vaccine for cysticercus cellulosae |
| 09/26/2001 | CN1071579C Process for preparing anti-body conjugates for treamtent of tumor disease |
| 09/25/2001 | US6294663 Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof |
| 09/25/2001 | US6294661 Compounds |
| 09/25/2001 | US6294654 Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region |
| 09/25/2001 | US6294652 Response regulator |
| 09/25/2001 | US6294523 Extended type 1 chain glycosphingolipids as tumor-associated antigens |
| 09/25/2001 | US6294383 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 09/25/2001 | US6294378 Method and reagents for genetic immunization |
| 09/25/2001 | US6294377 Adenoviral vectors of canine origin |
| 09/25/2001 | US6294344 Detecting tumor of urogenetial system in humans; obtain sample of human tissue, detect chymotrypsin enzyme in sample, the presence of amplified expression of chymotrypsin is indictive of tumor |
| 09/25/2001 | US6294343 Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators |
| 09/25/2001 | US6294340 Method of binding material to the β-amyloid peptide |
| 09/25/2001 | US6294322 Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| 09/25/2001 | US6294177 Particularly useful in the treatment of mastitis. |
| 09/25/2001 | US6294175 Compounds |
| 09/25/2001 | US6294174 Peptides immunologically related to known viral protein |
| 09/25/2001 | US6294173 Methods for treating a tumor containing fibrin using a fibrin specific monoclonal antibody and compositions used therein |
| 09/25/2001 | US6294172 Monoclonal antibodies with specificity for membrane-associated antigens |
| 09/25/2001 | US6294171 Methods for treating disease states comprising administration of low levels of antibodies |
| 09/25/2001 | US6294169 Interleukin-1 beta converting enzyme like apoptotic protease-6 |
| 09/25/2001 | US6294165 Vectors and their use in gene transfer. based on retroviruses, adapted so that they cannot package their own rna, and which can be used as infectious agents to transfer foreign genes, e.g. for somatic gene therapy. |
| 09/25/2001 | US6294153 Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| 09/25/2001 | CA2110058C Hepatitis c virus (hcv) polypeptides |
| 09/21/2001 | WO2001068118A1 Method for reducing allergen-induced airway hyperresponsiveness |
| 09/21/2001 | CA2403690A1 Method for reducing allergen-induced airway hyperresponsiveness |
| 09/20/2001 | WO2001069259A1 Method for detecting guanylyl cyclase and use thereof for diagnosing metastatic colorectal tumours |
| 09/20/2001 | WO2001068903A1 Modulating production of pneumococcal capsular polysaccharide |
| 09/20/2001 | WO2001068896A1 Treatment of allergies |
| 09/20/2001 | WO2001068889A2 Method for gene transfection and vaccination through skin using electropermeabilization |
| 09/20/2001 | WO2001068865A2 Fish vaccine against piscirickettsia salmonis |
| 09/20/2001 | WO2001068860A1 Antibodies to human cd154 |
| 09/20/2001 | WO2001068858A2 Human g protein-coupled receptors |
| 09/20/2001 | WO2001068853A2 Immunogenic ovarian cancer genes |
| 09/20/2001 | WO2001068851A2 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | WO2001068849A2 Human ion channels |
| 09/20/2001 | WO2001068820A1 Altered strain of the modified vaccinia virus ankara (mva) |
| 09/20/2001 | WO2001068819A1 Improved methods to isolate, identify, quantify, and propagate chicken infectious anemia virus and high titer vaccine |
| 09/20/2001 | WO2001068802A2 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 09/20/2001 | WO2001068708A2 Human and humanized fap-alpha-specific antibodies |
| 09/20/2001 | WO2001068704A2 G-protein coupled receptors |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |
| 09/20/2001 | WO2001068682A1 Self antigen vaccines for treating b cell lymphomas and other cancers |
| 09/20/2001 | WO2001068679A2 Peptides targeting specifically tumor-derived endothelial cells |
| 09/20/2001 | WO2001068677A2 Derivatives of breast canacer antigen her-2 for therapeutical use |
| 09/20/2001 | WO2001068158A1 Coating that promotes endothelial cell adherence |
| 09/20/2001 | WO2001068146A2 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/20/2001 | WO2001068144A2 Biodegradable immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068143A2 Immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068134A2 Therapies that improve graft survival, using antibodies against a b7 antigen |
| 09/20/2001 | WO2001068133A1 Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
| 09/20/2001 | WO2001068132A1 Use of a combination of agents that modulate b7 activity in inhibiting intestinal allograft rejection |
| 09/20/2001 | WO2001068129A2 Adjuvant for vaccines |
| 09/20/2001 | WO2001068128A1 Pneumococcus polysaccharide conjugates for use as vaccine against tetanus and diphtheria |
| 09/20/2001 | WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |